-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
Academician of Chinese Academy of Engineering, Academician of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Professor Kong Beihua of Qilu Hospital of Shandong University, Professor Liu Jihong of Sun Yat-sen University Cancer Center, Professor Wu Lingying of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Wu Xiaohua of Fudan University Cancer Hospital and Chongqing University Professor Zhou Qi from the Cancer Hospital and other well-known experts and scholars in the industry and gynecological tumor experts from all over the country attended the meeting to discuss the new situation of targeted therapy for ovarian cancer in China
All experts agreed that the inclusion of fluzoparib in medical insurance will provide more options for the treatment of ovarian cancer and further reduce the economic burden of patients
Fluzoparib is China's first self-developed PARP inhibitor and the seventh innovative drug developed and marketed by Hengrui
Fluzoparib has been approved for marketing and included in medical insurance, which better meets the needs of patients and brings high-quality and affordable options to patients, as well as a better quality of life
On February 19, 2022, the listing meeting of Fluzoparib Medical Insurance was held in Qingdao offline, and the main venue Qingdao, Beijing, Henan, Anhui, Hubei and Guizhou were held online.
, 7 sub-venues in Guangdong and Chongqing are linked in real time
.
Academician of Chinese Academy of Engineering, Academician of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Professor Kong Beihua of Qilu Hospital of Shandong University, Professor Liu Jihong of Sun Yat-sen University Cancer Center, Professor Wu Lingying of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Wu Xiaohua of Fudan University Cancer Hospital and Chongqing University Professor Zhou Qi from the Cancer Hospital and other well-known experts and scholars in the industry and gynecological tumor experts from all over the country attended the meeting to discuss the new situation of targeted therapy for ovarian cancer in China
Ai Ruiyi (fluzoparib) medical insurance listing will be linked online and offline venues
At the meeting, experts discussed the challenges faced by ovarian cancer in China, the research layout of fluzoparib and the latest research progress
.
All experts agreed that the inclusion of fluzoparib in medical insurance will provide more options for the treatment of ovarian cancer and further reduce the economic burden of patients
Dai Hongbin, deputy general manager of Hengrui Medicine, delivered a speech on behalf of Hengrui Medicine.
He pointed out that Hengrui Medicine has carried out a rich R&D layout in the field of tumor treatment
.
Fluzoparib is China's first self-developed PARP inhibitor and the seventh innovative drug developed and marketed by Hengrui
The meeting came to an end, but the efforts to benefit Chinese ovarian cancer patients never stopped
.
Fluzoparib has been approved for marketing and included in medical insurance, which better meets the needs of patients and brings high-quality and affordable options to patients, as well as a better quality of life
